Role, indications, and controversies of antidepressant therapy in chronic stroke patients

European Journal of Physical and Rehabilitation Medicine

Volumn 49, Issue 2, 2013, Pages 233-241

  Paolucci, S ^a  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Antidepressive agents; Depression.; Mood disorders

Indexed keywords

EID: 84881440272     PISSN: 19739087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Hatcher S, Arroll B. Newer antidepressants for the treatment of depression in adults. BMJ 2012;344:d8300.
2. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005;36:1330-40. (Pubitemid 40798764)
3. SPREAD - Stroke Prevention and Educational Awareness Diffusion. Ictus cerebrale: linee guida italiane di prevenzione e trattamento. http://www spreadit/2010. Available at: URL: http:// www.spread.it/.
4. El Husseini N, Goldstein LB, Peterson ED, Zhao X, Pan W, Olson DM et al. Depression and antidepressant use after stroke and transient ischemic attack. Stroke 2012;43:l609-l6.
5. Paolucci S, Di VA, Massicci R, Traballesi M, Bureca I, Matano A et al. Impact of participation on rehabilitation results: a multivariate study. Eur J Phys Rehabil Med 2012;48:455-66.
6. Valuck RJ, Libby AM, Orton HD, Morrato EH, Allen R, Baldessarini RJ. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2007;164:1198-205. (Pubitemid 47292408)
7. Gill D, Hatcher S. A systematic review of the treatment of depression with antidepressant drugs in patients who also have a physical illness. J Psychosom Res 1999;47:131-43. (Pubitemid 29468890)
8. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996;37:12-6. (Pubitemid 26021814)
9. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004;91:119-28. (Pubitemid 38120206)
10. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry 2004;65:1642-53.
11. Kharofa J, Sekar P, Haverbusch M, Moomaw C, Flaherty M, Kissela B, Broderick J, Woo D. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke 2007;38:3049-51. (Pubitemid 350035702)
12. Chen Y, Guo JJ, Patel NC. Hemorrhagic stroke associated with antidepressant use in patients with depression: does degree of serotonin reuptake inhibition matter? Pharmacoepidemiol Drug Saf 2009;18:196-202.
13. Howland RH. A critical evaluation of the cardiac toxicity of Citalopram: part 2. J Psychosoc Nurs Ment Health Serv 2011;49:13-6.
14. Howland RH. A question about the potential cardiac toxicity of escitalopram. J Psychosoc Nurs Ment Health Serv 2012,50:17-20.
15. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13-37. (Pubitemid 34296308)
16. Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology 2010;86:203-15.
17. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551.
18. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58.
19. Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 2003;54:376-87. (Pubitemid 37267864)
20. Paolucci S. Epidemiology and treatment of post-stroke depression. Neuropsychiatr Dis Treat 2008;4:145-54. (Pubitemid 351460985)
21. Paolucci S, Gandolfo C, Provinciali L, Torta R, Toso V, on behalf of DESTRO Study Group. The Italian multicenter observational study on post-stroke depression (DESTRO). J Neurol 2006;253:556-62. (Pubitemid 43876983)
22. Dahmen N, Marx J, Hopf HC, Tettenborn B, Roder R. Therapy of early poststroke depression with venlafaxine: safety, tolerability, and efficacy as determined in an open, uncontrolled clinical trial. Stroke 1999;30:691-2. (Pubitemid 29115413)
23. Kimura M, Kanetani K, Imai R, Suzuki H, Isayama K, Endo S. Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression. Int Clin Psychopharmacol 2002;17:121-5. (Pubitemid 34442193)
24. Yamakawa Y, Satoh S, Sawa S, Ohta H, Asada T. Efficacy of milnacipran on poststroke depression on inpatient rehabilitation. Psychiatry Clin Neurosci 2005;59:705-10. (Pubitemid 43151664)
25. Cravello L, Caltagirone C, Spalletta G. The SNRI venlafaxine improves emotional unawareness in patients with post-stroke depression. Hum Psychopharmacol 2009;24:331-6.
26. Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database Syst Rev 2008;CD003437.
27. Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS. Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovasc Dis 2008,26:266-71.
28. Paul SL, Dewey HM, Sturm JW, Macdonell RA, Thrift AG. Prevalence of depression and use of antidepressant medication at 5-years poststroke in the North East Melbourne Stroke Incidence Study. Stroke 2006;37:2854-5. (Pubitemid 44922553)
29. Gonzalez-Torrecillas JL, Mendlewicz J, Lobo A. Effects of early treatment of poststroke depression on neuropsychological rehabilitation. Int Psychogeriatr 1995;7:547-60. (Pubitemid 26105909)
30. Gainotti G, Antonucci G, Marra C, Paolucci S. Relation between depression after stroke, antidepressant therapy, and functional recovery. J Neurol Neurosurg Psychiatry 2001;71:258-61. (Pubitemid 32675158)
31. Bilge C, Kocer E, Kocer A, Turk BU. Depression and functional outcome after stroke: the effect of antidepressant therapy on functional recovery. Eur J Phys Rehabil Med 2008;44:13-8.
32. Narushima K, Robinson RG. The effect of early versus late antidepressant treatment on physical impairment associated with poststroke depression: is there a time-related therapeutic window? J Nerv Ment Dis 2003;191:645-52. (Pubitemid 37296176)
33. Mikami K, Jorge RE, Adams HP Jr, Davis PH, Leira EC, Jang M et al. Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry 2011;19:1007-15.
34. Jorge RE, Acion L, Moser D, Adams HP Jr, Robinson RG. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry 2010;67:187-96.
35. Dobkin BH. Neurobiology of rehabilitation. Ann N Y Acad Sci 2004;1038:148-70. (Pubitemid 40577456)
36. Berends HI, Nijlant J, van PM, Movig KL, Ijzerman MJ. Single dose of fluoxetine increases muscle activation in chronic stroke patients. Clin Neuropharmacol 2009;32:1-5.
37. Gladstone DJ, Black SE. Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier? Can J Neurol Sci 2000;27:97-105. (Pubitemid 30389894)
38. Feeney DM, De Smet AM, Rai S. Noradrenergic modulation of hemiplegia: facilitation and maintenance of recovery. Restor Neurol Neurosci 2004;22:175-90. (Pubitemid 39468279)
39. Martinsson L, Hardemark H, Eksborg S. Amphetamines for improving recovery after stroke. Cochrane Database Syst Rev 2007;CD002090.
40. Berends HI, Nijlant JM, Movig KL, Van Putten MJ, Jannink MJ, Ijzerman MJ. The clinical use of drugs influencing neurotransmitters in the brain to promote motor recovery after stroke; a Cochrane systematic review. Eur J Phys Rehabil Med 2009;45:621-30.
41. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-9. (Pubitemid 36962615)
42. Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des 2005;11:145-55. (Pubitemid 40089838)
43. Wang JW, David DJ, Monckton JE, Battaglia F, Hen R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci 2008;28:1374-84. (Pubitemid 351231535)
44. Jacobs BL, Fornal CA. 5-HT and motor control: a hypothesis. Trends Neurosci 1993;16:346-52. (Pubitemid 23232006)
45. Jacobs BL, Fornal CA. Serotonin and motor activity. Curr Opin Neurobiol 1997;7:820-5. (Pubitemid 28052305)
46. Loubinoux I, Pariente J, Boulanouar K, Carel C, Manelfe C, Rascol O et al. A Single Dose of the Serotonin Neurotransmission Agonist Paroxetine Enhances Motor Output: Double-Blind, Placebo-Controlled, fMRI Study in Healthy Subjects. Neuroimage 2002;15:26-36. (Pubitemid 34852202)
47. Loubinoux I, Pariente J, Rascol O, Celsis P, Chollet F. Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects. Neuropsychologia 2002;40:1815-21. (Pubitemid 34626429)
48. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegie patients undergoing rehabilitation therapy. Stroke 1996;27:1211-4. (Pubitemid 26226957)
49. Miyai I, Reding MJ. Effects of antidepressants on functional recovery following stroke: a double-blind study. J Neuro Rehab 1998;12:5-13. (Pubitemid 28213351)
50. Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001;50:718-29. (Pubitemid 33116131)
51. Allaman I, Fiumelli H, Magistretti PJ, Martin JL. Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology (Berl) 2011;216:75-84.
52. Gaillard R, Mir O. Fluoxetine and motor recovery after ischaemic stroke. Lancet Neurol 2011;10:499-1.
53. Huang Y, Chen W, Li Y, Wu X, Shi X, Geng D. Effects of antidepressant treatment on N-acetyl aspartate and choline levels in the hippocampus and thalami of post-stroke depression patients: a study using (I)H magnetic resonance spectroscopy. Psychiatry Res 2010;182:48-52.
54. Acler M, Robol E, Fiaschi A, Manganotti P. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol 2009;256:1152-8.
55. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011;10:123-30.
56. Zittel S, Weiller C, Liepert J. Reboxetine improves motor function in chronic stroke. A pilot study. J Neurol 2007;254:197-201. (Pubitemid 46356052)
57. Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair 2008;22:311-4. (Pubitemid 351561669)
58. Berends HI, Nijlant J, van PM, Movig KL, Ijzerman MJ. Single dose of fluoxetine increases muscle activation in chronic stroke patients. Clin Neuropharmacol 2009;32:1-5.
59. Ingles JL, Eskes GA, Phillips SJ. Fatigue after stroke. Arch Phys Med Rehabil 1999;80:173-8. (Pubitemid 29098408)
60. Staub F, Bogousslavsky J. Fatigue after stroke: a major but neglected issue. Cerebrovasc Dis 2001;12:75-81. (Pubitemid 32722241)
61. Choi-Kwon S, Han SW, Kwon SU, Kim JS. Poststroke fatigue: characteristics and related factors. Cerebrovasc Dis 2005;19:84-90. (Pubitemid 40278667)
62. Brainin M, Pinter M. Poststroke fatigue: a hint, but no definite word on therapy yet. Stroke 2012;43:933-4.
63. Naess H, Nyland HI, Thomassen L, Aarseth J, Myhr KM. Fatigue at long-term follow-up in young adults with cerebral infarction. Cerebrovasc Dis 2005;20:245-50. (Pubitemid 41318202)
64. Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS. Fluoxetine is not effective in the treatment of post-stroke fatigue: a doubleblind, placebo-controlled study. Cerebrovasc Dis 2007;23:103-8. (Pubitemid 46239148)
65. Engelter ST, FranK M, Lyrer PA, Conzelmann M. Safety of pharmacological augmentation of stroke rehabilitation. Eur Neurol 2010;64:325-30.
66. Engelter ST, Urscheler N, Baronti F, Vuadens P, Koch J, FranK M et al. Frequency and determinants of using pharmacological enhancement in the clinical practice of in-hospital stroke rehabilitation. Eur Neurol 2012;68:28-33.
67. Chollet F. Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A multicenter, randomized, double-blind, parallelgroup, placebo-controlled study. ClinicalTrials.gov Identifier: NCT01639014. http://www clinicaltrials gov/ 2012. Available at: http://www.clinicaltrials.gov/
68. Dejerine J, Roussy G. Le syndrome thalamique. Rev Neurol 1906;12:521-32.
69. Klit H, Finnerup NB, Jensen TS. Central post-stroke pain: clinical characteristics, pathophysiology, and management. Lancet Neurol 2009;8:857-68.
70. Kumar G, Soni CR. Central post-stroke pain: current evidence. J Neurol Sci 2009;284:10-7.
71. Henon H. Pain after stroke: a neglected issue. J Neurol Neurosurg Psychiatry 2006;77:569. (Pubitemid 43844574)
72. Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 2012;52:6-17.
73. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry 2010;81:1372-3.
74. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005;96:399-409. (Pubitemid 40835693)
75. Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. Drugs 2008;68:2611-32.
76. Leijon G, Boivie J. Central post-stroke pain-a controlled trial of amitriptyline and carbamazepine. Pain 1989;36:27-36. (Pubitemid 19024963)
77. Vranken JH, Hollmann MW, van der Vegt MH, Kruis MR, Heesen M, Vos K et al. Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial. Pain 2011;152:267-73.
78. Shimodozono M, Kawahira K, Kamishita T, Ogata A, Tohgo S, Tanaka N. Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine. Int J Neurosci 2002;112:1173-81. (Pubitemid 35293951)
79. Vestergaard K, Andersen G, Jensen TS. Treatment of centralpost-stroke pain with a selective serotonin reuptake inhibitor. Eur J Neurol 1996;3(Suppl 5):l69.
80. Canavero S, Bonicalzi V, Paolotti R. Reboxetine for central pain: a single-blind prospective study. Clin Neuropharmacol 2002;25:238-9. (Pubitemid 34832766)
81. Lampl C, Yazdi K, Roper C. Amitriptyline in the prophylaxis of central poststroke pain. Preliminary results of 39 patients in a placebo-controlled, long-term study. Stroke 2002;33:3030-2. (Pubitemid 35462883)
82. Frese A, Husstedt IW, Ringelstein EB, Evers S. Pharmacologic treatment of central post-stroke pain. Clin J Pain 2006;22:252-60. (Pubitemid 44378547)
83. Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-23.